GGrantIndex
← Leaderboards

Brent A French

University Of Virginia

$10,427,669
Attributed
$14,749,358
Total exposure
9
Grants
5
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $1.6M · FY200525
$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$14,749,358 · 9

By mechanism

R01$13,446,929 · 8
P01$1,302,429 · 1

Top collaborators

Most similar at University Of Virginia

Same institution · by research overlap

Others in their field

Top investigators on “Tissues

Research focus

TissuesMyocardial InfarctionHeartGene ExpressionAnimal ModelIn VivoMediatingClinically RelevantInflammationGene TherapyCardiacPathway InteractionsCell TypeMouse ModelMyocardial IschemiaCessation Of LifeGene DeliveryVectorAccountingInsightInterdisciplinary ApproachPlayCellsGenes

Grant awards (36)

Ultrasound Cavitation for Facilitated Cardiac Transduction of AAV$711,332
R01 · FY2025 · HL
Ultrasound Cavitation for Facilitated Cardiac Transduction of AAV$694,385
R01 · FY2024 · HL
Optical imaging in the development of molecularly targeted AAV for cardiac regeneration after myocardial infarction$403,750
R01 · FY2022 · HL · contact PI
Optical imaging in the development of molecularly targeted AAV for cardiac regeneration after myocardial infarction$403,750
R01 · FY2021 · HL · contact PI
Optical imaging in the development of molecularly targeted AAV for cardiac regeneration after myocardial infarction$403,750
R01 · FY2020 · HL · contact PI
Optical imaging in the development of molecularly targeted AAV for cardiac regeneration after myocardial infarction$403,750
R01 · FY2019 · HL · contact PI
A Bioengineering Approach to Gene Therapy for Peripheral Arterial Disease$691,315
R01 · FY2017 · HL
Highly Specific and Efficient Vectors for Targeting Pancreatic Cancer$489,556
R01 · FY2017 · CA
A Bioengineering Approach to Gene Therapy for Peripheral Arterial Disease$681,405
R01 · FY2016 · HL
Highly Specific and Efficient Vectors for Targeting Pancreatic Cancer$489,556
R01 · FY2016 · CA
Multi-parameter CMR of post-MI Left Ventricular Remodeling in Gene Modified Mice$384,096
R01 · FY2016 · HL · contact PI
A Bioengineering Approach to Gene Therapy for Peripheral Arterial Disease$675,558
R01 · FY2015 · HL
Highly Specific and Efficient Vectors for Targeting Pancreatic Cancer$489,556
R01 · FY2015 · CA
Multi-parameter CMR of post-MI Left Ventricular Remodeling in Gene Modified Mice$378,334
R01 · FY2015 · HL · contact PI
A Bioengineering Approach to Gene Therapy for Peripheral Arterial Disease$691,170
R01 · FY2014 · HL
Highly Specific and Efficient Vectors for Targeting Pancreatic Cancer$504,056
R01 · FY2014 · CA
Multi-parameter CMR of post-MI Left Ventricular Remodeling in Gene Modified Mice$376,414
R01 · FY2014 · HL · contact PI
Multi-parameter CMR of post-MI Left Ventricular Remodeling in Gene Modified Mice$365,659
R01 · FY2013 · HL · contact PI
Inflammation and Oxidative Stress in Hyperglycemic Exacerbation of Infarct Size$356,914
R01 · FY2013 · HL · contact PI
Inflammation and Oxidative Stress in Hyperglycemic Exacerbation of Infarct Size$374,910
R01 · FY2012 · HL · contact PI
Inflammation and Oxidative Stress in Hyperglycemic Exacerbation of Infarct Size$378,697
R01 · FY2011 · HL · contact PI
Inflammation and Oxidative Stress in Hyperglycemic Exacerbation of Infarct Size$378,697
R01 · FY2010 · HL · contact PI
Inflammation and Oxidative Stress in Hyperglycemic Exacerbation of Infarct Size$378,697
R01 · FY2009 · HL · contact PI
Cardiopulmonary Response to Lung Injury$334,750
P01 · FY2008 · HL · contact PI
Cardiopulmonary Response to Lung Injury$331,633
P01 · FY2007 · HL · contact PI
Cardiopulmonary Response to Lung Injury$218,311
P01 · FY2006 · HL · contact PI
GENE THERAPY FOR MYOCARDIAL STUNNING AND INFARCTION$214,076
R01 · FY2006 · HL · contact PI
GENE THERAPY FOR MYOCARDIAL STUNNING AND INFARCTION$219,309
R01 · FY2005 · HL
Cardiopulmonary Response to Lung Injury$211,954
P01 · FY2005 · HL
A2a ADENOSINE RECEPTOR IN REMOTE LV DYSFUNCTION POST-MI$367,228
R01 · FY2004 · HL
GENE THERAPY FOR MYOCARDIAL STUNNING AND INFARCTION$219,387
R01 · FY2004 · HL
Cardiopulmonary Response to Lung Injury$205,781
P01 · FY2004 · HL
A2a ADENOSINE RECEPTOR IN REMOTE LV DYSFUNCTION POST-MI$367,309
R01 · FY2003 · HL
GENE THERAPY FOR MYOCARDIAL STUNNING AND INFARCTION$219,463
R01 · FY2003 · HL
A2a ADENOSINE RECEPTOR IN REMOTE LV DYSFUNCTION POST-MI$367,387
R01 · FY2002 · HL
A2a ADENOSINE RECEPTOR IN REMOTE LV DYSFUNCTION POST-MI$367,463
R01 · FY2001 · HL